Table 2.
Preoperative patient characteristics
| Overall (n = 1509) | |
|---|---|
| Age (years), median (i.q.r.) | 66 (59–71) |
| Sex | |
| F | 287 (19.0) |
| M | 1222 (81.0) |
| BMI (kg/m2), median (i.q.r.) | 26 (23–29) |
| Missing | 123 (8.2) |
| Comorbidity | |
| ASA 1 | 143 (9.5) |
| ASA 2 | 845 (56.0) |
| ASA 3 | 469 (31.1) |
| ASA 4 | 19 (1.3) |
| Missing | 33 (2.2) |
| Performance status | |
| ECOG 0 | 666 (44.1) |
| ECOG 1 | 425 (28.2) |
| ECOG 2 | 88 (5.8) |
| ECOG 3 | 8 (0.5) |
| ECOG 4 | 3 (0.2) |
| Missing | 319 (21.1) |
| Tumour type | |
| Adenocarcinoma | 1088 (72.1) |
| SCC | 377 (25.0) |
| Other | 38 (2.5) |
| Missing | 6 (0.4) |
| Tumour location | |
| Cervical | 19 (1.3) |
| Upper thoracic | 54 (3.6) |
| Mid thoracic | 229 (15.2) |
| Lower thoracic | 779 (51.6) |
| GOJ | 418 (27.7) |
| Missing | 10 (0.7) |
| Clinical T-stage | |
| cTis | 17 (1.1) |
| cT1 | 169 (11.2) |
| cT2 | 298 (19.7) |
| cT3 | 926 (61.4) |
| cT4a | 48 (3.2) |
| cTx | 51 (3.4) |
| Clinical N-stage | |
| cN0 | 595 (39.4) |
| cN1 | 522 (34.6) |
| cN2 | 215 (14.2) |
| cN3 | 51 (3.4) |
| cN+ | 87 (5.8) |
| cNx | 39 (2.6) |
| Neoadjuvant treatment | |
| None | 301 (19.9) |
| Chemoradiotherapy | 352 (22.3) |
| Chemotherapy | 842 (55.8) |
| Radiotherapy | 6 (0.4) |
| Missing | 8 (0.5) |
Values are n (%) unless otherwise indicated. BMI, body mass index; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; SCC, squamous cell carcinoma; GOJ, gastro-oesophageal junction.